author-photo

Adeboye H. Adewoye

Boston University

42

Papers

878

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

477 COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246)

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT168: Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pathobiology of the Human Erythrocyte and Its Hemoglobins

2018
Show All
- Source
- Cite
- Save
Citations (3)
Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

2018 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (15)
Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (3)
Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)